Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Dec;85(6):702-769.
doi: 10.1016/j.jinf.2022.10.012. Epub 2022 Oct 13.

Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis

Huzaifa Ahmad Cheema  1 , Uzair Jafar  2 , Asmaa Ahmed Elrashedy  3 , Abia Shahid  2 , Rehmat Ullah Awan  4 , Muhammad Ehsan  2 , Muhammad Ayyan  2 , Syeda Sahra  5
Affiliations
Meta-Analysis

Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis

Huzaifa Ahmad Cheema et al. J Infect. 2022 Dec.
No abstract available

Keywords: COVID-19; Fluvoxamine; SARS-CoV-2; SSRIs.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors report no relationships that could be construed as a conflict of interest.

Figures

Fig 1
Fig. 1
Effect of fluvoxamine on: (A) all-cause mortality and (B) hospitalization in COVID-19 patients.
See this image and copyright information in PMC

Comment in

References

    1. Qian Z., Pengfei M., Mingwei W., Yongran C., Mengyun Z., Lan Ye, et al. Efficacy and safety of Paxlovid for COVID-19:a meta-analysis. J Infect. 2022 doi: 10.1016/j.jinf.2022.09.027. - DOI - PMC - PubMed
    1. Junzheng W., Jacob L., Leah E., Andrew H. Minimum manufacturing costs, national prices, and estimated global availability of new repurposed therapies for Coronavirus Disease 2019. Open Forum Infect Dis. 2022;9(1) doi: 10.1093/ofid/ofab581. - DOI - PMC - PubMed
    1. Maurish F., Saleha A., Junaid S., Abia S., Cheema H.A. Efficacy and safety of molnupiravir for COVID-19 patients. Eur J Intern Med. 2022;102:118–121. doi: 10.1016/j.ejim.2022.05.024. - DOI - PMC - PubMed
    1. Rayner Craig R., Louis D., Park Jay J.H., Decloedt Eric H., Cotton Mark F., Vis N., et al. Accelerating clinical evaluation of repurposed combination therapies for COVID-19. Am J Trop Med Hyg. 2020;103(4):1364–1366. doi: 10.4269/ajtmh.20-0995. - DOI - PMC - PubMed
    1. Sukhatme Vikas P., Reiersen Angela M., Vayttaden Sharat J., Sukhatme Vidula V. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021;12:763. doi: 10.3389/fphar.2021.652688. - DOI - PMC - PubMed